Disagree
Home Substances
CJC-1295 with DAC

CJC-1295 with DAC

A-Z
Search for:
Substance Overview and History

CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), designed to increase the release of growth hormone (GH) from the pituitary gland. Developed by a company name ConjuChem in Montreal and first described in 2005. Its became known for its long-lasting effects due to its binding with serum albumin, extending its half-life to 8-10 days. It is very popular for its muscle-building and fat-loss benefits. Despite promising research, clinical development was halted in 2006 after a participant death in a trial.

References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ
What is CJC-1295?
CJC-1295 is a synthetic analog of GHRH that stimulates growth hormone release.
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

How does CJC-1295 work?
It increases GH release from the pituitary gland, leading to higher IGF-1 levels.
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

What benefits does CJC-1295 offer?
As per research results it promotes muscle growth, fat loss, and anti aging effects.
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.